Novartis wins GBCHealth Business Action on Health Award for social ventures initiative
17 May 2013 | By Novartis
"We are proud to be recognized by GBCHealth for our Arogya Parivar program..."
List view / Grid view
17 May 2013 | By Novartis
"We are proud to be recognized by GBCHealth for our Arogya Parivar program..."
10 May 2013 | By Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab)...
8 May 2013 | By Novartis
"Lucentis was designed to save sight..."
25 April 2013 | By Novartis
"We believe that this innovative campaign will help speed malaria elimination..."
24 April 2013 | By Novartis
Novartis announced the compensation for the incoming Chairman of the Board, starting August 1, 2013...
23 April 2013 | By Novartis
Results from the 64-week SPARK study...
19 April 2013 | By Novartis
A new beta blocker-free, fixed-combination therapy for glaucoma patients...
1 April 2013 | By Novartis
Novartis has never been granted an original patent for Glivec in India...
26 March 2013 | By Novartis
Latest global patient-use data...
21 March 2013 | By Novartis
New data presented...
18 March 2013 | By Novartis
Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole...
15 March 2013 | By Novartis
First filing for LDK378 anticipated in early 2014...
13 March 2013 | By Novartis
New data will be presented...
1 March 2013 | By Novartis
Novartis announced that the European Commission has approved llaris (canakinumab, ACZ885)...
28 February 2013 | By Novartis
Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka...